Last reviewed 2026-05-22 · How we verify

Kaoxidin (SUCCINYLSULFATHIAZOLE)

Phase 2 active Small molecule ✓ Verified May 2026

Kaoxidin (generic name: SUCCINYLSULFATHIAZOLE) is a succinylsulfathiazole drug. It is currently in Phase 2 development.

Kaoxidin works by inhibiting bacterial growth through its antimicrobial properties.

Kaoxidin is a small molecule with synonyms including Colistatin, Cremosuxidine, Guanicar, and others. It is classified as a small molecule modality.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SUCCINYLSULFATHIAZOLE
Drug class	succinylsulfathiazole
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Think of Kaoxidin like a strong antibiotic that helps stop the growth of bad bacteria in the body. It does this by interfering with the bacteria's ability to make copies of themselves, which ultimately helps to clear up infections. This is similar to how other antibiotics work, but the exact details of Kaoxidin's mechanism are not well understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Kaoxidin CI brief — competitive landscape report
Kaoxidin updates RSS · CI watch RSS

Frequently asked questions about Kaoxidin

What is Kaoxidin?

Kaoxidin (SUCCINYLSULFATHIAZOLE) is a succinylsulfathiazole drug.

How does Kaoxidin work?

Kaoxidin works by inhibiting bacterial growth through its antimicrobial properties.

What is the generic name of Kaoxidin?

SUCCINYLSULFATHIAZOLE is the generic (nonproprietary) name of Kaoxidin.

What drug class is Kaoxidin in?

Kaoxidin belongs to the succinylsulfathiazole class. See all succinylsulfathiazole drugs at /class/succinylsulfathiazole.

What development phase is Kaoxidin in?

Kaoxidin is in Phase 2.

Drug class: All succinylsulfathiazole drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing